Lipfendra (enlicitide) is the first FDA-approved oral, once-daily PCSK9 inhibitor.
The medication serves as an adjunct therapy to diet, exercise, and statins for adults with hypercholesterolemia.
Unlike injectable predecessors, Lipfendra is a macrocyclic peptide tablet stored at room temperature.
List price is approximately $315 for a 30-day supply, significantly lower than initial injectable pricing.